2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1014

Regulatory Role of IL-23 and Its Receptor System in Spondyloarthritis and Its Therapeutic Relevance in anti-IL-17 Failure Patients

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1315

Relation of MRI-detected Structural Damage in the Patellofemoral Joint to Pain and Performance Based Function: The MOST Study

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1440

Relationship Between Adalimumab Concentrations, Plasma Cytokines, Anti-drug Antibodies and Disease Activity in Rheumatoid Arthritis

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1362

Relationship Between Waking Functions and Disease Activity in Rheumatoid Arthritis Patients Analyzed by Wearable Device

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1633

Relationship Between YKL-40, VEGF, and IL-5 in Borderline mPAP and Pulmonary Hypertension in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1105

Relationships Among Cognitive Emotion Regulation, Body Image, Family and Marital Function and Quality of Life in Chinese Female Patients with Systemic Lupus Erythematosus

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1222

Relationships Between Allopurinol Dose, Oxypurinol Levels and Serum Urate – in Search of an Oxypurinol Therapeutic Concentration

Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

9:00AM-11:00AM: Abstract Number: 1684

Remission and Low Disease Activity State in Patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1564

Renal Arteriosclerosis Predicts Cardiovascular Disease in Lupus Nephritis

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1018

Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans

SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1528

Resolution of Enthesitis and Dactylitis Is Maintained over Two Years of Ixekizumab Treatment in Patients with Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1279

Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management

Muscle Biology, Myositis & Myopathies Poster II

9:00AM-11:00AM: Abstract Number: 1179

Resting-State Functional Connectivity of Pain Processing Brain Region Associated with Therapeutic Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis

Imaging Of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1429

Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1512

Retention Rates and Response of Anti-TNF Treatments in the Enteropathic Spondylitis: HUR-BIO Real Life Results

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].